Formulation and Evaluation of Mesalamine Nanosphere Tablet
Nanospheres are the particles having the size range between 10-200 nm in diameter. Nanospheres can be amorphous or crystalline in nature and also they have the ability to protect the drug from enzymatic and chemical degradation. For the preparation of standard calibration curve of Mesalamine with Phosphate buffer pH 6.8 and Absorbance of µg/ml solution was measured between 200-400nm by using Shimadzu 1601 UV/Vis double beam spectrophotometer. Nanosphare containing Mesalamine were prepared using nanoprecipitation method. 200 mg of polymer (Eudragit RS and L) was dissolve in 50 ml water. Drug was dissolve in 20 ml of methanol. Both solution were mixed and add 50 ml of water and stirred for half an hour. Methanol and water was evaporated under reduced pressure using rotary flash evaporator until 10 ml of solution was remaining. Than this suspension was centrifuge at 15000 rpm at 40C for half an hour. The supernatant was discarded and remaining portion was washed with distilled water. The nano-sphares was dried over night at 600C and stored in desiccators. The surface morphology (roundness, smoothness, and formation of aggregates) and particle size was studied by scanning electron microscopy (SEM). Zeta potential of the best formulation (F4) was determined by zeta potential probe model DT- 300. Mesalamimne, Dextrose and Lactose were taken in required quantities mixed and granulating agent (Starch past) was added and passed through #40 sieves, then lubricant magnesium stearate and talc was added then compressed into tablets by rotary tablet punching machine. Then film coating is done by 6% w/v solution of Cellulose acetate Phthalate in isopropyl alcohol using 2% tween-80 as plasticizer in coating pan. The weight of tablet was kept constant for all formulations. Nanosphare tablet formulation F-2 Showed maximum drug (97.75%) released and formulation F-4 showed 92.58% drug release. The In-vitro drug released study result showed that formulation F-2 96.58% drug was released after 17 hours which is highest drug release amongst all other tablet formulation.
2. Singh A., Garg G., Sharma P.K., Nanospheres: A Novel Approach for Targeted Drug Delivery System International Journal of Pharmaceutical Sciences Review and Research Volume 5,3, 2010, 34-38.
3. Ramteke K.H., Joshi S.A., Dhole S.N., Solid Lipid Nanoparticle: A Review IOSR Journal of PharmacyVolume 2,6 2012, 34-44.
4. Dangi A.A., Ganur e A.L., Jain D., Formulation and Evaluation of Colon Targeted Drug Delivery System of Levetiracetam Using Pectin as Polymeric CarrierJournal of Applied Pharmaceutical Science Vol-3 (1) 2013, 78-87.
5. Prasanth V.V., Jayaprakash R., MathewS.,T.Colon Specific Drug Delivery Systems: AReview on Various Pharmaceutical Approaches Journal of Applied Pharmaceutical Science, Vol-2 (1) 2012, 163-169.
6. Colson P., Henrist C., ClootsR.,Nanosphere Lithography: A Powerful Method for the Controlled Manufacturing of Nanomaterials Journal of Nanomaterials 2013, 1-19.
7. Gupta V.K., Gnanarajan G., Kothiya P., A Review Article on Colonic Targeted Drug Delivery SystemThe Pharma Innovation Vol-12012, 14-24.
8. Mahajan. P.D., Sarode S.M., Sathe, B.S., Jain P.V., Jain B.V., Vadnere G.P., Formulation and Evaluation of Colon Specific Drug Delivery system of zaltoprofen World Journal of Pharmacy and Pharmaceutical Sciences Vol-3 (3) 2014, 933-952.
9. Singh R., Formulation and evaluation of colon targeted drug delivery System International Journal of Pharmacy & Life Sciences Vol-3(12) 2012, 2265-2268.
10. Singh P.K., Kumar S.,.Easwari T.S., Shukla V.K., Sharan G., Formulation Development and Evaluation of Colon Targeted Dosage form of IbuprofenInternational Journal of Pharma Sciences and ResearchVol-3, 2012,268-178.
11. Purushothaman M., Kalvimoorthi V., Formulation and Evaluation of Colon Targeted Drug Delivery System of Flurbiprofen using HPMC and K4M Sodium Alginate as Polymeric Carrier International Journal of ChemTech ResearchVol-10 2017, 156-168.
12. Kolte B.P., Tele K.V., Mundhe V.S., Lahoti S.S.,Colon Targeted Drug Delivery System – A Novel Perspective Asian Journal of Biomedical and Pharmaceutical SciencesVol-2(14) 2012, 21-28.
13. Vijaykumar N., Venkateswarlu V., Raviraj P.,Development of oral tablet dosage form incorporating drug nanoparticles Research Journal of Pharmaceutical, Biological and Chemical Sciences Vol-1(4) 2010, 953-963.
14. Gupta D.K., Razdan B.K., Bajpai M., Formulation and Evaluation of Nanoparticles Containing Artemisinin HClInternational Journal of Research and Development in Pharmacy and Life SciencesVol-3(2), 2014, 925-934.
15. Tamizhrasi S., Shukla A., Shivkumar T., Rathi V., Rathi J.C., Formulation and Evaluation of Lamivudine Loaded Polymethacrylic Acid Nanoparticles International Journal of PharmTech Research Vol-1(3) 2009, 411-415.
16. Heera P., Shanmugam S., Nanoparticle Characterization and Application: An Overview International Journal of Current Microbiol and Applied Science Vol-4(8) 2015, 379-386.
17. Zainab E.J., Hussein A.A., Formulation and Evaluation of Clopidogrel Tablet Incorporating Drug Nanoparticles International Journal of Pharmacy and Pharmaceutical Sciences Vol 6 (1) 2014, 838-851.
18. Garg M., Srivastava B., Kohli K., Bedi S. Sharma P., Improved Performance of Celecoxib Tablets Using Nanoparticle Approach Pharmacophore 2014, Vol. 5 (3), 378-387.
19. Sharma N., Harikumar S.L., Polymers for Colon Targeted Drug Delivery: A Review International Journal of Drug Development & Research Vol-5(1) 2013, 21-31.
20. Garud A., Singh D., GarudN., Solid Lipid Nanoparticles (SLN): Method, Characterization and ApplicationsInternational Current Pharmaceutical Journal Vol-1 (11) 2012, 384-393
21. Sadiq A.A., Alaa A.R., Formulation and Evaluation of Silibinin Loaded Solid Lipid Nanoparticles for Peroral Use Targeting Lower Part of Gastrointestinal Tract International Journal of Pharmacy and Pharmaceutical Sciences Vol-6(1) 2014, 55-67.
22. Nair R., Vishnu priya K., Arun Kumar K.S., Badivaddin T., Sevukarajan M., Formulation and Evaluation of Solid Lipid Nanoparticles of Water Soluble Drug: IsoniazidJournal of Pharmaceutical Science & Research Vol-3(5) 2011,1256-1264.
23. Ekambaram P., Abdul H.A., Priyanka K., Solid Lipid Nanoparticles: A ReviewScience Reviews Chemical Communication Vol-2(1), 2012, 80-102.
27. Rowe R.C., Sheskey P.J., Quinn M.E., Hsandbook of Pharmaceutical Excipient Published by the Pharmaceutical Pressand the American Pharmacists Association Sixth edition 2009 159-160, 145-146, 278-279, 231-232, 385-386, 430-431, 767-768.
28. Kinget R, KalalaW, Vervoort L, vandenMooter G., Colonic drug targeting. J DrugTargeting 1998; 6(2): 129-149.
29. Rathod S., Colon Targeted Pulsatile DrugDelivery: A Review. Pharm Rev. 2007; 5(2).
30. Krishnaiaha. Y.S.R, Satyanarayana. V, Dineshkumar. B, Karthikeyan. R.S, Eur J Pharm Sci2002; 16:185–192.
31. Krishnaiah. Y.S.R, Bhaskar Reddy. P.R, Satyanarayana. V, Karthikeyan. R.S. Int JPharm, 2002; 236(2):43-55.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).